Struthers Richard Scottinsider trades
In SEC Form 4 filings, Struthers Richard Scott is listed as President & CEO of Crinetics Pharmaceuticals, Inc. (CRNX). Struthers Richard Scott reported no open-market purchases or sales in the last 90 days. The latest Form 4 transaction on record was filed on Sep 1.
Companies and roles
| Company | Role | Transactions | Last filed |
|---|---|---|---|
| CRNXCrinetics Pharmaceuticals, Inc. | President & CEO | 20 | Sep 1 |
Cluster buys
No cluster buy in the last 90 days included a purchase by this insider (two or more insiders buying within 14 days).
Form 4 historysince 2026-09-01
| Company | Traded | Filed | Type | Shares | Price | Value | Owned after | 10b5-1 plan | Filing |
|---|---|---|---|---|---|---|---|---|---|
| CRNXCrinetics Pharmaceuticals, Inc. | Sep 1 | Sep 1 | D | 248,043 | $85.00 | $21,083,655 | 176,663 | No | Form 4 |
| CRNXCrinetics Pharmaceuticals, Inc. | Sep 1 | Sep 1 | D | 1,000 | $85.00 | $85,000 | not reported | No | Form 4 |
| CRNXCrinetics Pharmaceuticals, Inc. | Sep 1 | Sep 1 | D | 136,805 | $85.00 | $11,628,425 | not reported | No | Form 4 |
| CRNXCrinetics Pharmaceuticals, Inc. | Sep 1 | Sep 1 | D | 106,000 | $85.00 | $9,010,000 | not reported | No | Form 4 |
| CRNXCrinetics Pharmaceuticals, Inc. | Sep 1 | Sep 1 | D | 110,000 | $85.00 | $9,350,000 | not reported | No | Form 4 |
| CRNXCrinetics Pharmaceuticals, Inc. | Sep 1 | Sep 1 | D | 100,000 | $85.00 | $8,500,000 | not reported | No | Form 4 |
| CRNXCrinetics Pharmaceuticals, Inc. | Sep 1 | Sep 1 | D | 111,100 | $85.00 | $9,443,500 | not reported | No | Form 4 |
| CRNXCrinetics Pharmaceuticals, Inc. | Sep 1 | Sep 1 | D | 111,100 | $85.00 | $9,443,500 | not reported | No | Form 4 |
| CRNXCrinetics Pharmaceuticals, Inc. | Sep 1 | Sep 1 | D | 111,100 | $85.00 | $9,443,500 | not reported | No | Form 4 |
| CRNXCrinetics Pharmaceuticals, Inc. | Sep 1 | Sep 1 | D | 111,100 | $85.00 | $9,443,500 | not reported | No | Form 4 |
| CRNXCrinetics Pharmaceuticals, Inc. | Sep 1 | Sep 1 | D | 80,000 | $85.00 | $6,800,000 | not reported | No | Form 4 |
| CRNXCrinetics Pharmaceuticals, Inc. | Sep 1 | Sep 1 | D | 176,663 | $85.00 | $15,016,355 | not reported | No | Form 4 |
| CRNXCrinetics Pharmaceuticals, Inc. | Sep 1 | Sep 1 | D · derivative | 172,281 | $59.81 | $10,304,127 | not reported | No | Form 4 |
| CRNXCrinetics Pharmaceuticals, Inc. | Sep 1 | Sep 1 | D · derivative | 195,578 | $62.39 | $12,202,111 | not reported | No | Form 4 |
| CRNXCrinetics Pharmaceuticals, Inc. | Sep 1 | Sep 1 | D · derivative | 259,058 | $69.71 | $18,058,933 | not reported | No | Form 4 |
| CRNXCrinetics Pharmaceuticals, Inc. | Sep 1 | Sep 1 | D · derivative | 244,205 | $64.98 | $15,868,441 | not reported | No | Form 4 |
| CRNXCrinetics Pharmaceuticals, Inc. | Sep 1 | Sep 1 | D · derivative | 287,700 | $65.36 | $18,804,072 | not reported | No | Form 4 |
| CRNXCrinetics Pharmaceuticals, Inc. | Sep 1 | Sep 1 | D · derivative | 240,000 | $41.49 | $9,957,600 | not reported | No | Form 4 |
| CRNXCrinetics Pharmaceuticals, Inc. | Sep 1 | Sep 1 | D · derivative | 313,000 | $48.14 | $15,067,820 | not reported | No | Form 4 |
| CRNXCrinetics Pharmaceuticals, Inc. | Sep 1 | Sep 1 | D · derivative | 228,000 | $41.21 | $9,395,880 | not reported | No | Form 4 |
Published from this insider's public Form 4 filings on SEC EDGAR; the name is shown as filed. Named in a filing and want this page removed? See the privacy policy.